CGON Leonard E Post sells $30K worth of shares
Jan 15, 2025, 5:33 AM
-9.06%
What does CGON do
CG Oncology, based in Irvine, California, focuses on developing bladder-sparing therapies for bladder cancer and went public on January 25, 2024. Its key candidates include cretostimogene and BOND-003, both targeting non-muscle invasive bladder cancer.
Leonard E Post sold 1,000 shares of CGON on 13 January at $29.66 per share, worth a total of $30K. They now own 0 CGON shares, or a 100% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!